Navigation Links
Intarcia Presents Positive ITCA 650 Phase 2 Study Results for Type 2 Diabetes at EASD
Date:9/22/2010

HAYWARD, Calif., Sept. 22 /PRNewswire/ -- Intarcia Therapeutics, Inc. presented today final results of a 24-week phase 2 clinical study of ITCA 650 (DUROS® continuous subcutaneous delivery of exenatide) for the treatment of type 2 diabetes at the 46th Annual Meeting of the European Association for the Study of Diabetes in Stockholm, Sweden.

(Logo: http://photos.prnewswire.com/prnh/20050301/SFTU126LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20050301/SFTU126LOGO)

Results of the phase 2 study demonstrated substantial reductions in HbA1c and body weight during the 24 weeks of treatment with ITCA 650 at all doses.  A starting ITCA 650 dose of 20 mcg/day for weeks 1 through 12 provided effective glycemic control with the best tolerability profile.  A transition to ITCA 650 at 60 mcg/day for weeks 13 through 24 was well tolerated and provided substantial incremental reductions in both HbA1c and body weight at week 24. An ITCA 650 treatment regimen involving a 20 mcg/day starting dose with a transition to 60 mcg/day after week 12 has been selected for a phase 3 clinical trial, anticipated to begin enrollment in early 2011.

"We are very encouraged by the results observed in this study and the high level of enthusiasm expressed by patients and investigators," said Kurt Graves, executive chairman of the board for Intarcia. "ITCA 650 is a novel therapeutic approach for type 2 diabetes that holds new promise for many patients and physicians who want highly effective glucose reductions and weight loss without the tradeoff associated with having to start potentially lifelong and frequent self-injections." Graves added, "ITCA 650 also holds the promise to ensure patient compliance and long-term control given the breakthrough nature of its continuous delivery with just one or two placements
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
2. Intarcia Therapeutics Names Kurt Graves Executive Chairman to Advance Strategic Interests and Broaden Commercial Goals
3. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
4. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
5. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
6. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
7. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
8. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
9. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
10. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
11. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... Oct. 1, 2014 Trovagene, Inc., (NASDAQ: ... today that Eli Diamond , MD, Assistant ... (MSK), presented clinical data from an ongoing study ... platform for the determination of oncogene mutational status ... The results were presented to both treating physicians ...
(Date:10/1/2014)... , Oct. 1, 2014   Cypher Genomics, Inc., ... of J. Patrick Ravenel as chief technology ... software and systems experience and a proven track record ... "Patrick has been recognized as a ... systems and is known industry-wide for delivering innovative products ...
(Date:10/1/2014)... 1, 2014 Quantum Materials Corp (OTCQB:QTMM) ... of photoactive quantum dots for use in ... numerous advantages for solar power generation, the high ... quantum dots with which to develop thin film ... commercial utilization and acceptance. The company is also ...
Breaking Medicine Technology:Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 2Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 3Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 4Cypher Genomics Appoints J. Patrick Ravenel Chief Technology Officer 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 3
... growing appetite for health and wellness devices, and this represents ... been tapped, according to a study from IBM (NYSE: ... wellness device innovations of the future, which have the potential ... healthcare provider over the next five years. (Photo: ...
... 2011 Providers of durable medical equipment and services (DME) ... repeal Medicare,s controversial "competitive" bidding for homecare, which cuts quality ... The program is opposed by the ... advocacy groups such as the ALS Association and ...
Cached Medicine Technology:IBM Study Identifies New Generation of Connected Health Devices 2IBM Study Identifies New Generation of Connected Health Devices 3IBM Study Identifies New Generation of Connected Health Devices 4IBM Study Identifies New Generation of Connected Health Devices 5At-Home Care Businesses Urge President Obama to Repeal Medicare Program that Cuts Access to Homecare 2At-Home Care Businesses Urge President Obama to Repeal Medicare Program that Cuts Access to Homecare 3At-Home Care Businesses Urge President Obama to Repeal Medicare Program that Cuts Access to Homecare 4
(Date:10/1/2014)... First Warning Systems, a pioneer in ... throughout the body, announced the company is changing its ... company’s breadth of upcoming product releases. The initial focus ... , “Our initial focus will be an ‘Internet of ... circadian cellular changes over time,” said Rob Royea, president ...
(Date:10/1/2014)... new genetic finding from Duke Medicine suggests that some ... might also be hard-wired to gain weight when exposed ... , An estimated 13 percent of people, all of ... knowing this could help them reduce heart disease with ... stress management. , "Genetic susceptibility, psychosocial stress and metabolic ...
(Date:10/1/2014)... NoteSwift Inc., announced today their new NoteSwift™ 2.0 ... NoteSwift is the bridge between the EHR and Dragon ... clinical information at the point of care. NoteSwift reduces ... by more than half – and virtually eliminates mouse ... state impedes EHR use according to the June 12, ...
(Date:10/1/2014)... 01, 2014 Nordic Naturals is ... very special cause. The campaign—“Buy One Bottle. Help ... for Veterans, a nonprofit organization that helps rebuild ... shelter dogs that would otherwise face euthanasia. From ... will support monthly donations of Nordic Naturals omega-3s ...
(Date:10/1/2014)... October 01, 2014 Two bicyclists began ... them across the country in an effort to raise ... families. The cyclists, a father-daughter team, plan to ... in Blaine, Washington and finishing in Key West Florida. ... For The Warriors®, a national nonprofit organization that assists ...
Breaking Medicine News(10 mins):Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:NoteSwift Joins Allscripts Developer Program 2Health News:NoteSwift Joins Allscripts Developer Program 3Health News:Nordic Naturals® Inspires Support for Paws for Veterans -- ‘Buy One Bottle. Help Two Heroes.’ Initiative Kicks Off October 1 2Health News:Father-Daughter Cycling Duo to Ride Cross-Country to Benefit Hope For The Warriors 2
... hope to detect the disease while it is still ... scientists say they have found small molecules in the ... could have diagnostic implications in the future. , Levels ... suffering from pancreatic cancer, the fourth-leading cancer killer in ...
... harsh skin toxicity associated with a widely used cancer drug, ... Cancer Biology and Therapy by researchers from City of ... (Erbitux) is a monoclonal antibody that binds to and inhibits ... to treat colorectal cancer and head and neck cancer. Although ...
... combined with a defibrillator (CRT-D) implanted had a 34 ... failure when compared to patients receiving only an implanted ... online today in the New England Journal of ... of Cardiology Congress (ESC) in Barcelona, Spain. The overall ...
... is available in French . , ... serious autoimmune disorders which cause muscular inflammation are at ... of Montreal researchers. Dr. Christian A. Pineau and his ... Health Centre (RI-MUHC) have linked muscular inflammation to increased ...
... , , , , ... in grants for four Northwest nonprofits: HealthMatters of Central Oregon ... Northwest Organization of Nurse Executives . The grants all ... increase access to care. , , "At The Regence ...
... , PITTSBURGH, Sept. 1 On Friday, September 18, ... former president of the renowned public relations agency Porter Novelli, former ... native William (Bill) D. Novelli. Enjoy lunch and a presentation ... to accomplish this, and what it means for seniors in the ...
Cached Medicine News:Health News:Blood Test May Spot Pancreatic Cancer Early 2Health News:Prodrug could help curb skin toxicity related to EGFR-inhibiting cancer drugs 2Health News:Stuy in NEJM: New therapy prevents heart failure 2Health News:Researchers link inflammatory diseases to increased cardiovascular risk 2Health News:Regence Foundation Awards Nearly $250,000 in Grants to Northwest Nonprofits 2
... Hand Instruments were developed in surgeon's desire ... still having an instrument with the strength ... fear of the bending or breaking. Arthrotek ... to conform to the surgeon's hand. This ...
The narrow shaft and compact jaw design facilitates access and use in tight spaces, particularly useful in the posterior aspect of the knee....
... Hand Instruments were developed in surgeon's desire ... still having an instrument with the strength ... fear of the bending or breaking. Arthrotek ... to conform to the surgeon's hand. This ...
... Instruments were developed in surgeon's desire to ... having an instrument with the strength to ... of the bending or breaking. Arthrotek Hand ... conform to the surgeon's hand. This new ...
Medicine Products: